Compare Applovin Corporation (APP) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Applovin Corporation vs Merck & Co., Inc. — how do they compare? Applovin Corporation trades at $447 (market cap $170.31B), while Merck & Co., Inc. trades at $123.41 (market cap $305.12B). The key difference: Merck & Co., Inc. is the larger of the two by market cap, and Merck & Co., Inc. pays a 2.75% dividend while Applovin Corporation pays none. Which is the better fit depends on your goals.
| APP | MRK | |
|---|---|---|
Market Cap | $170.31B | $305.12B |
Sector | Technology | Health |
52-Week High | $733.60 | $129.52 |
52-Week Low | $335.10 | $77.60 |
Enterprise Value | $171.07B | $348.54B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AppLovin trades at $506.98, down 2.58% today, with a bullish technical setup near pivot point support at $504. The company shows exceptional fundamentals with 59% revenue growth in Q1 2026 and net margins exceeding 64%. Analyst consensus remains strongly bullish with an $644.09 price target, supported by expanding e-commerce advertising share and AI-driven platform growth noted in recent Jefferies research.
The outlook remains positive given consistent earnings beats and projected revenue growth to $6.2B in 2026. Primary risks include premium valuation multiples (P/E 44.09) and competitive pressure in mobile advertising. The stock offers growth exposure but requires monitoring of execution against high expectations.
MRK trades at $123.65, up 0.09% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 loss narrower than expected. Revenue grew to $65.01B in 2025, and net income margin improved to 28.07%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, signaling strategic growth initiatives.
Outlook remains positive with a consensus price target of $135.14, offering ~9% upside. Risks include rising debt-to-asset ratio to 36.06% in 2025 and projected net cash flow decline in 2026. Institutional buying activity supports bullish sentiment, but competitive pressures and macroeconomic factors warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Applovin Corporation
AppLovin provides a software platform for mobile app developers to market, monetize, and analyze their apps. Its AI-powered tools help developers grow their business by connecting them with global advertising networks.
Read more on APP →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
